Logo Logo Logo Logo Logo
  • About Us
    • About Odylia
    • Our Board
    • Our Team
    • Our Partners
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
  • About Us
    • About Odylia
    • Our Board
    • Our Team
    • Our Partners
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd

Join us to learn about plans for the RPGRIP1 Gene Therapy Program in 2022. Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of these benchmarks and what it means for the program. We'll also discuss the plans...

21 January, 2022
Services
  • Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors
  • Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer
  • Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd
Odylia Therapeutics logo

© 2022 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs